文献速递脑血管病

3K3A-活化蛋白C变体不干扰替奈普酶血浆凝块溶解活性

3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase.
PubMed 文献 · Stroke · 2020-06-17

该体外研究评估3K3A-APC对替奈普酶诱导的人血浆凝块溶解的影响。结果显示3K3A-APC在替奈普酶极低水平时缩短凝块溶解时间,但在较高治疗浓度下无此效应,且替奈普酶与阿替普酶在3K3A-APC存在下表现相似,表明3K3A-APC不干扰替奈普酶的溶栓功能。

要点

  • 3K3A-APC不干扰替奈普酶对血浆凝块的溶解功能。
  • 极低水平替奈普酶时3K3A-APC缩短凝块溶解时间,治疗浓度下无影响。
  • 替奈普酶与阿替普酶在3K3A-APC存在下溶栓行为相似。

核心结论

  • 3K3A-APC不干扰替奈普酶的血浆凝块溶解功能。

研究设计与样本

  • 体外研究,使用人正常混合血浆经凝血酶生成的凝块,监测不同剂量3K3A-APC存在下替奈普酶介导的溶解。

主要发现

  • 3K3A-APC在替奈普酶极低水平时缩短凝块溶解时间,但在较高治疗浓度替奈普酶时无此效应。
  • 替奈普酶与阿替普酶在3K3A-APC存在下溶栓行为相似。

关键数值与推荐

  • 3K3A-APC缺乏抗凝特性(<10%)而保留抗炎、抗凋亡和神经保护功能。

临床怎么用

  • 支持3K3A-APC与替奈普酶联合用于急性缺血性卒中治疗的进一步研究。

局限性

  • 为体外研究,结果需临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: A recombinant engineered variant of APC (activated protein C), 3K3A-APC, lacks anticoagulant properties (<10%) while preserving APCs anti-inflammatory, anti-apoptotic, and neuroprotective functions and is very promising in clinical trials for ischemic stroke. Therapeutic intervention with single bolus administration of the third-generation tPA (tissue-type plasminogen activator), tenecteplase, is anticipated to be widely adopted for treatment of acute ischemic stroke. 3K3A-APC is well-tolerated in stroke patients dosed with alteplase, and in vitro studies show 3K3A-APC does not interfere with alteplase-induced clot lysis. The purpose of this in vitro study was to assess the influence of 3K3A-APC on tenecteplase-induced clot lysis. METHODS: Tenecteplase-mediated lysis of thrombin generated plasma clots of human normal pooled plasma was monitored in the presence of varying doses of 3K3A-APC. The effects on fibrinolysis by tenecteplase and alteplase were compared. RESULTS: The presence of 3K3A-APC shortened the time for clot lysis induced by tenecteplase at very low levels but not at higher therapeutic concentrations of tenecteplase. Comparisons of alteplase-mediated clot lysis to tenecteplase clot lysis showed that both thrombolytic agents behaved similarly in the presence of 3K3A-APC. CONCLUSIONS: These results indicate that 3K3A-APC does not interfere with tenecteplase's clot lysis function.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Mukherjee P, Lyden P, Fernández JA, et al. 3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase. Stroke. 2020. PMID: 32568648. doi:10.1161/STROKEAHA.120.028793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。